Lane Zhang, MD
Clinical Cardiac Electrophysiology · Chattanooga, TNNPI 1316359508
Payments from drug & device makers
What this record shows
This record is dominated by grants: $26,583 of the $35,823 with a category attached, or 74.2%. 32 manufacturers reported payments, led by Medtronic at 46.4% of the total. Reporting peaked in 2020 at $19,675 and has fallen 89.0% since, to $2,163 in 2025.
Across 218 payments — averaging $164.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$17K
- Boston Scientific$9K
- Abbott$6K
- Biosense Webster, Inc.$754
- Novartis$530
- Cardiva Medical, Inc.$486
- plus $2K from 26 others
What the payments were for
- Grants$26,58374%
- Travel & lodging$1,9095%
- Food & beverage$7,09720%
- Education$2341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 43 | $16,609 |
| Boston Scientific | 16 | $9,177 |
| Abbott | 25 | $5,910 |
| Biosense Webster, Inc. | 32 | $754 |
| Novartis | 20 | $530 |
| Cardiva Medical, Inc. | 16 | $486 |
| AstraZeneca | 5 | $290 |
| Abiomed | 2 | $262 |
| Atricure, Inc. | 4 | $216 |
| E.r. Squibb & Sons, L.L.C. | 7 | $213 |
| Pfizer | 10 | $180 |
| Medical Device Business Services, Inc. | 1 | $160 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $142 |
| Amarin Pharma, Inc. | 1 | $120 |
| Merck | 4 | $90 |
| Novo Nordisk | 5 | $89 |
| Heartflow, Inc. | 1 | $88 |
| Amgen | 3 | $70 |
| Johnson & Johnson | 2 | $69 |
| Boehringer Ingelheim | 3 | $59 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Vital Connect, Inc | 1 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $31 |
| Cvrx, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Bayer | 1 | $19 |
| Terumo Medical Corporation | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BRADY$5,000
- TactiCath SE$4,500
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$3,750
- Carto 3$301
- ENSITE$285
- Impella$262
- ENTRESTO$209
- AVEIR$203
- ADVISOR$165
- ENSITE PRECISION$143
- Ensite Cardiac Mapping System$135
- PulseSelect$130
- SelectSecure$122
- Vascepa$120
- Micra$113
- Farapulse$109
- ELIQUIS$109
- AZURE XT DR MRI SURESCAN$105
- SYMPLICITY G3$104
- NA$102
How this compares
$35,823 in reported general payments places this provider in the 75th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.
See all clinical cardiac electrophysiology providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 153 | $143,445 |
| XareltoRivaroxaban | 46 | $42,993 |
| FarxigaDapagliflozin Propanediol | 28 | $19,189 |
| MultaqDronedarone Hcl | 26 | $18,797 |
| EntrestoSacubitril/Valsartan | 20 | $12,203 |
| Amiodarone Hcl | 67 | $1,218 |
| SotalolSotalol Hcl | 64 | $1,153 |
| Metoprolol Succinate | 86 | $831 |
| Flecainide Acetate | 23 | $561 |
| ClopidogrelClopidogrel Bisulfate | 37 | $461 |
| Amlodipine Besylate | 47 | $308 |
| Rosuvastatin Calcium | 20 | $259 |
| Losartan Potassium | 37 | $220 |
| Pantoprazole Sodium | 23 | $204 |
| Carvedilol | 30 | $182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $180 | $143,445153 claims |
| Johnson & JohnsonXarelto | $69 | $42,99346 claims |
| AstraZenecaFarxiga | $290 | $19,18928 claims |
| Sanofi-aventis U.S. LLCMultaq | $43 | $18,79726 claims |
| NovartisEntresto | $530 | $12,20320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.
Other clinical cardiac electrophysiology in Chattanooga
- Harish ManyamChattanooga$265K
- Augustus MealorChattanooga$18K
- Timothy TalbertChattanooga$8K
- Kelly RichardsonChattanooga$4K
- Stephen FahrigNashville$605K
- Gregory BashianNashville$361K
- William StevensonNashville$172K
- Sandeep DuggalNashville$151K
- Sean WhalenNashville$149K
- David LanGermantown$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.